Literature DB >> 18505610

[Epidemiological environment and response to the HIV epidemic in Bolivia].

Juan Pablo Protto1, Diddie Schaaf, Marco Fidel Suárez, Christian Darras.   

Abstract

With AIDS/HIV, early detection is of key importance to public health, as well as disseminating prevention information and providing timely and appropriate treatment. In Bolivia, at the end of 2006 approximately 50% had AIDS at the time of diagnosis, detection having occurred late in the illness. The HIV/AIDS epidemic in Bolivia is concentrated, with prevalence rates over 5% among the at-risk population, primarily men who have sex with men. From January 1984 through October 2006, the total number of HIV/AIDS cases reported in Bolivia rose to 2 190, with 1 239 HIV and 951 AIDS cases, and underreporting estimated to be over 70% country-wide. The United National Joint Program on AIDS (UNAIDS) estimated that by the end of 2006 there would be 6 700 people living with HIV/AIDS in Bolivia. In the context of this scenario, the article describes the challenges facing the HIV/AIDS program and the strategies developed to address the epidemic in Bolivia. In addition, the UNAIDS/PAHO strategies are stressed and must get underway for HIV/AIDS prevention and control activities in the country.

Entities:  

Mesh:

Year:  2008        PMID: 18505610     DOI: 10.1590/s1020-49892008000400012

Source DB:  PubMed          Journal:  Rev Panam Salud Publica        ISSN: 1020-4989


  2 in total

1.  The HIV-1 epidemic in Bolivia is dominated by subtype B and CRF12_BF "family" strains.

Authors:  Monick L Guimarães; Ketty G Velarde-Dunois; David Segurondo; Mariza G Morgado
Journal:  Virol J       Date:  2012-01-16       Impact factor: 4.099

2.  Knowledge, attitudes and practices on HIV/AIDS and prevalence of HIV in the general population of Sucre, Bolivia.

Authors:  Carolina Terán Calderón; Dorian Gorena Urizar; Cristina González Blázquez; Belén Alejos Ferreras; Oriana Ramírez Rubio; Francisco Bolumar Montrull; Marta Ortiz Rivera; Julia del Amo Valero
Journal:  Braz J Infect Dis       Date:  2015-05-19       Impact factor: 3.257

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.